Verano Holdings (VRNO) Cash & Equivalents (2021 - 2026)
Verano Holdings' (VRNO) quarterly Cash & Equivalents came in at $74.0 million in Q1 2026, down 12.1% year-on-year from $84.2 million in Q1 2025, and down 10.51% on a QoQ basis from $82.7 million in Q4 2025.
Verano Holdings (VRNO) Cash & Equivalents (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has 6 years of Cash & Equivalents data on file, last reported at $74.0 million in Q1 2026.
- On a quarterly basis, Cash & Equivalents fell 12.1% year-over-year to $74.0 million in Q1 2026; TTM through Mar 2026 was $74.0 million, a 12.1% decrease from a year earlier, with the FY2025 full-year figure at $82.7 million, down 5.78% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $74.0 million, down from $82.7 million in the prior quarter.
- Over the last five years, Cash & Equivalents for VRNO reached as high as $193.8 million in Q1 2024 and fell as low as $65.0 million in Q3 2024.
- Historically, Cash & Equivalents has averaged $101.6 million across 5 years, with a median of $86.3 million in 2022.
- Across the five-year window, Cash & Equivalents jumped 105.96% in 2023 and slumped 56.54% in 2025, its largest moves.
- Year by year, Cash & Equivalents stood at $84.9 million in 2022, then soared by 105.96% to $174.8 million in 2023, then plunged by 49.76% to $87.8 million in 2024, then fell by 5.78% to $82.7 million in 2025, then slipped by 10.51% to $74.0 million in 2026.
- Per Business Quant data, the three most recent Cash & Equivalents figures were $74.0 million in Q1 2026, $82.7 million in Q4 2025, and $82.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 1.76 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 3.79 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 1.28 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 266.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Verano Holdings | 2.02 Bn | 1.94 Bn | 98.98 Mn | 74.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 74.03 Mn |
| Dec 31, 2025 | 82.72 Mn |
| Sep 30, 2025 | 82.62 Mn |
| Jun 30, 2025 | 68.57 Mn |
| Mar 31, 2025 | 84.22 Mn |
| Dec 31, 2024 | 87.80 Mn |
| Sep 30, 2024 | 64.98 Mn |
| Jun 30, 2024 | 130.05 Mn |
| Mar 31, 2024 | 193.80 Mn |
| Dec 31, 2023 | 174.76 Mn |
| Sep 30, 2023 | 129.92 Mn |
| Jun 30, 2023 | 102.58 Mn |
| Mar 31, 2023 | 95.13 Mn |
| Dec 31, 2022 | 84.85 Mn |
| Sep 30, 2022 | 76.42 Mn |
| Jun 30, 2022 | 92.83 Mn |
| Dec 31, 2021 | 99.12 Mn |